Advance system testing: Benefit‐risk analysis of a marketed vaccine using cohort modelling and MCDA swing weighting

Aug-18

Database General Analysis Virology and Immunisations

AUTHORS : Kaatje Bollaerts, P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001 Heverlee, Belgium (Vlierbeeklaan 18, 3010 Kessel-lo, Belgium) – Email: kaatje.bollaerts@p-95.com

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 27(S2):12-13

DOI : 10.1002/pds.4629

Advance system testing: Benefit‐risk analysis of a marketed vaccine using cohort modelling and MCDA swing weighting

More publications

Characteristics and Outcomes of Over a Million Patients with Infammatory Bowel Disease in Seven Countries: Multinational Cohort Study and Open Data Resource

Defining Mental Health Conditions Within Primary Care Data: A Validation Study With a Mixed Qualitative and Quantitative Approach

The risk of immune-mediated inflammatory diseases following exposure to childhood maltreatment: a retrospective cohort study using UK primary care data